People: Trinity Biotech PLC (TRIB.O)


TRIB.O on Nasdaq

17.15USD
18 Jun 2013
Price Change (% chg)

$0.15 (+0.88%)
Prev Close
$17.00
Open
$17.05
Day's High
$17.39
Day's Low
$17.02
Volume
11,821
Avg. Vol
59,949
52-wk High
$19.00
52-wk Low
$11.25

Search Stocks

Summary

Name Age Since Current Position

Ronan O'Caoimh

 57 2011 Executive Chairman of the Board

Kevin Tansley

 42 2007 Chief Financial Officer, Secretary

Rory Nealon

 45 2007 Chief Operating Officer, Executive Director

James Walsh

 54 2010 Chief Scientific Officer, Executive Director

Clinton Severson

 64 2008 Non-Executive Director

Denis Burger

 68 2010 Senior Non-Executive Independent Director

Peter Coyne

 53 2001 Non-Executive Independent Director

James Merselis

 59 2009 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

Ronan O'Caoimh

 Mr. Ronan O'Caoimh serves as the Executive Chairman of the Board of Trinity Biotech PLC. He co-founded Trinity Biotech in June 1992 and acted as Chief Financial Officer until March 1994 when he became Chief Executive Officer. He was also elected Chairman in May 1995. In November 2007, it was decided to separate the role of Chief Executive Officer and Chairman and Mr O’Caoimh assumed the role of Executive Chairman. In October 2008, following the resignation of the Chief Executive Officer, Mr. O’Caoimh resumed the role of Chief Executive Officer and Chairman. Prior to joining Trinity Biotech, Mr O’Caoimh was Managing Director of Noctech Limited, an Irish diagnostics company. Mr O’Caoimh was Finance Director of Noctech Limited from 1988 until January 1991 when he became Managing Director. Mr. O’Caoimh holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland. On March 30, 2011, the service agreement with Ronan O’Caoimh as Chief Executive Officer was terminated and replaced by an agreement with Darnick Limited.

Kevin Tansley

 Mr. Kevin Tansley is Chief Financial Officer, Secretary of Trinity Biotech PLC. He joined Trinity Biotech in June 2003 and was appointed Chief Financial Officer and Secretary to the Board of Directors in November 2007. Prior to joining Trinity Biotech in 2003, Mr Tansley held a number of financial positions in the Irish electricity utility ESB. Mr. Tansley holds a Bachelor of Commerce degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

Rory Nealon

 Mr. Rory Nealon is Chief Operating Officer, Executive Director of Trinity Biotech PLC. He joined Trinity Biotech as Chief Financial Officer and Company Secretary in January 2003. He was appointed Chief Operations Officer in November 2007. Prior to joining Trinity Biotech, he was Chief Financial Officer of Conduit plc, an Irish directory services provider with operations in Ireland, the UK, Austria and Switzerland. Prior to joining Conduit he was an Associate Director in AIB Capital Markets, a subsidiary of AIB Group plc, the Irish banking group. Mr. Nealon holds a Bachelor of Commerce degree from University College Dublin, is a Fellow of the Institute of Chartered Accountants in Ireland, a member of the Institute of Taxation in Ireland and a member of the Institute of Corporate Treasurers in the UK.

James Walsh

 Dr. James Walsh, Ph.D., is Chief Scientific Officer, Executive Director of Trinity Biotech PLC. He initially joined Trinity Biotech in October 1995 as Chief Operations Officer. Dr. Walsh resigned from the role of Chief Operations Officer in 2007 to become a Non Executive Director of the Company. In October, 2010 Dr. Walsh rejoined the company as Chief Scientific Officer. Prior to joining Trinity Biotech, Dr Walsh was Managing Director of Cambridge Diagnostics Ireland Limited (CDIL). He was employed with CDIL since 1987. Before joining CDIL he worked with Fleming GmbH as Research & Development Manager. Dr Walsh holds a PhD in Chemistry from University College Galway.

Clinton Severson

 Mr. Clinton H. Severson is Non-Executive Director of Trinity Biotech PLC. Mr. Severson joined the board of Trinity Biotech in November 2008 as a non-executive director. Mr Severson is currently Chairman, President and CEO of Abaxis Inc., a NASDAQ traded diagnostics company based in Union City, California. From February 1989 to May 1996, Mr. Severson served as President and Chief Executive Officer of MAST Immunosystems, Inc., a privately-held medical diagnostic company and to date he has accumulated over 30 years experience in the medical diagnostics industry.

Denis Burger

 Dr. Denis R. Burger, Ph.D. serves as Senior Non-Executive Independent Director of Trinity Biotech PLC. He co-founded Trinity Biotech in June 1992 and was Chairman from June 1992 to May 1995. He is currently Chairman of BioCurex, Inc, a cancer diagnostics, OTC:BB listed company and is also non-executive director of Lorus Therapeutics, Inc, a cancer therapeutics, TSX listed company. Until March 2007, Dr Burger was the Chairman and Chief Executive Officer of AVI Biopharma Inc, a NASDAQ listed biotechnology company. He was also a co-founder and, from 1981 to 1990, Chairman of Epitope Inc. In addition, Dr Burger has held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his degree in Bacteriology and Immunology from the University of California in Berkeley in 1965 and his Master of Science and PhD in 1969 in Microbiology and Immunology from the University of Arizona.

Peter Coyne

 Mr. Peter Coyne serves as Non-Executive Independent Director of Trinity Biotech PLC. He joined the board of Trinity Biotech in November 2001 as a non-executive director. Mr Coyne is a director of AIB Corporate Finance and has experience in advising public and private groups on all aspects of corporate strategy. Mr. Coyne trained as a chartered accountant and was a senior manager in Arthur Andersen’s Corporate Financial Services practice. Mr. Coyne holds a Bachelor of Engineering degree from University College Dublin and is a Fellow of the Institute of Chartered Accountants in Ireland.

James Merselis

 Mr. James D. Merselis is Non-Executive Independent Director of Trinity Biotech PLC. Mr. Merselis is currently a consultant to healthcare diagnostics companies. Mr. Merselis was formerly President and CEO of ITC Nexus Dx, Inc., a privately held diagnostics company working to improve patient care by providing rapid and reliable Point-of-Care (POC) medical test information. Prior to this Mr. Merselis served as President and CEO of Alverix, Inc., a privately held company developing portable medical diagnostic instruments. From 2002 to 2007, Mr. Merselis served as President and CEO of HemoSense, Inc. (AMEX: HEM), a Point-of-Care diagnostics company providing patients and physicians with rapid test results to help manage the risk of stroke with the use of warfarin or Coumadin. Prior to his tenure at HemoSense, Mr. Merselis served as President and CEO of Micronics, Inc., a microfluidics company. In addition, Mr. Merselis held a series of increasingly responsible executive positions over twenty-two years with Boehringer Mannheim Diagnostics (now Roche Diagnostics).

Basic Compensation

Name Fiscal Year Total

Ronan O'Caoimh

 881,000

Kevin Tansley

 476,000

Rory Nealon

 576,000

James Walsh

 448,000

Clinton Severson

 --

Denis Burger

 --

Peter Coyne

 --

James Merselis

 --
As Of 30 Dec 2012

Options Compensation

Name Options Value

Ronan O'Caoimh

 0 0

Kevin Tansley

 0 0

Rory Nealon

 0 0

James Walsh

 0 0

Clinton Severson

 0 0

Denis Burger

 0 0

Peter Coyne

 0 0

James Merselis

 0 0

Insider Trading

» Full list on Insider Trading
Search Stocks